Profusa, Inc. (PFSA) Stock
Profusa stock price chart
PFSA stock quote & key statistics
Profusa annual financials
Income statement →| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $0 | -$35.8M | -$696.93 |
| FY2024 | $0 | -$9.2M | -$11153.00 |
| FY2023 | $0 | -$10.3M | $1033.95 |
| FY2022 | $0 | -$20.2M | $2224.28 |
| FY2021 | $0 | -$10.3M | — |
Fiscal year ending December 31. Source: company filings via EODHD.
About Profusa, Inc.
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
Profusa stock FAQ
What is the Profusa stock ticker symbol?
Profusa, Inc. trades on the NASDAQ under the ticker symbol PFSA.
What sector and industry is Profusa in?
Profusa, Inc. is classified in the Healthcare sector, Medical Devices industry.
What were Profusa's revenue and earnings last fiscal year?
Profusa reported revenue of $0 and net income of -$35.8M in fiscal 2025, with earnings per share of -$696.93.
When did Profusa go public?
Profusa stock began trading on July 11, 2025.
Medical Devices stocks
All Healthcare stocks →- ABTAbbott
- AHCOAdaptHealth
- BIOBio-Rad Laboratories
- BRKRBruker
- BSXBoston Scientific
- CNMDCONMED
- DXCMDexCom
- ENOVEnovis
- EWEdwards Lifesciences
- GEHCGE HealthCare
- GMEDGlobus Medical
- HAEHaemonetics
- IARTIntegra LifeSciences
- ITGRInteger
- LIVNLivaNova
- LMRILumexa Imaging
- MDTMedtronic
- PENPenumbra
- PODDInsulet
- QDELQuidelOrtho
- STESteris
- SYKStryker
- TNDMTandem Diabetes Care
- ZBHZimmer Biomet